Skip to content
Expert in Metabolic Dysfunction-associated Steatohepatitis

Explore our industry-leading
translational models of
NASH/MASH & HCC

Gubra’s flagship model GAN DIO-MASH is top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our model portfolio and latest findings to ensure a successful preclinical study.

Explore our data

Download the Latest Posters


Check out our posters and discover the clinical translatability of our flagship GAN DIO-MASH model, as well as other biopsy-confirmed preclinical models.

Standard Study Outlines

We are experts in bridging preclinical and clinical development.


MICHAEL FEIGH
Vice President, Scientific Sales

Michael’s primary focus is on MASH (NASH), MASH-HCC (NASH-HCC), IPF and IBD. Michael provides customers with scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.

Let’s meet at the EASL 2023

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top